Breast cancer drug shows promise in those resistant to trastuzumab

07/28/2009 | Reuters

A midstage trial showed at least five partial responses in terms of tumor shrinkage to a combination of trastuzumab and Ariad Pharmaceuticals' breast cancer treatment ridaforolimus. The study involved patients with metastatic breast cancer who had developed resistance to trastuzumab.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC